Prostate Cancer Prostatic Dis
-
Publication Venue For
-
Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?.
26:151-155.
2023
-
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer..
26:30-40.
2023
-
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415.
2023
-
Urinary microbiota and prostatic diseases: the key for the lock? A systematic review.
2022
-
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial..
25:597.
2022
-
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer..
25:388-396.
2022
-
Racial disparities in prostate cancer among black men: epidemiology and outcomes..
25:397-402.
2022
-
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer..
25:762-769.
2022
-
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate..
25:800-801.
2022
-
Editor' summary: A paradigm shift in castration-resistant prostate cancer management..
25:601-603.
2022
-
KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression..
25:749-754.
2022
-
Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial..
25:770-777.
2022
-
Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer.
2022
-
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)..
25:58-64.
2022
-
Correction: Public interest in dietary supplements for prostate cancer prevention..
25:376.
2022
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk..
25:274-282.
2022
-
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial..
25:363-365.
2022
-
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials..
25:288-295.
2022
-
Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis..
25:165-173.
2022
-
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)..
25:306-313.
2022
-
Association between environmental quality and prostate cancer stage at diagnosis..
24:1129-1136.
2021
-
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate..
24:1032-1040.
2021
-
Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer..
24:725-732.
2021
-
Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer..
24:786-793.
2021
-
Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?.
24:507-513.
2021
-
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies..
24:301-309.
2021
-
The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer..
24:335-340.
2021
-
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer..
24:81-87.
2021
-
Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort..
24:120-127.
2021
-
Public interest in dietary supplements for prostate cancer prevention..
24:58-60.
2021
-
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer..
23:680-688.
2020
-
Androgen receptor variant-driven prostate cancer II: advances in clinical investigation..
23:367-380.
2020
-
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations..
23:381-397.
2020
-
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry..
23:517-526.
2020
-
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)..
23:66-73.
2020
-
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC..
23:160-171.
2020
-
Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men..
22:580-587.
2019
-
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer..
22:531-538.
2019
-
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials..
22:522-530.
2019
-
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients..
22:588-592.
2019
-
A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial..
22:428-437.
2019
-
Correction: Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy..
22:350.
2019
-
Estrogens and prostate cancer..
22:185-194.
2019
-
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series..
22:309-316.
2019
-
Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy..
22:268-275.
2019
-
Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis..
22:159-167.
2019
-
Updates in advanced prostate cancer 2018..
21:449-450.
2018
-
Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?.
21:419-430.
2018
-
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation..
21:306-318.
2018
-
Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer..
21:196-203.
2018
-
Platinum sensitivity in metastatic prostate cancer: does histology matter?.
21:92-99.
2018
-
Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?.
20:323-327.
2017
-
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project..
20:294-299.
2017
-
Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy..
20:241-248.
2017
-
Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model..
20:165-171.
2017
-
Is prostate cancer stage migration continuing for black men in the PSA era?.
20:210-215.
2017
-
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL..
20:221-227.
2017
-
Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort..
19:423-428.
2016
-
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting..
19:231-241.
2016
-
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science..
19:111-121.
2016
-
Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer..
19:40-45.
2016
-
Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence..
18:310-316.
2015
-
Computed high b-value diffusion-weighted imaging improves lesion contrast and conspicuity in prostate cancer..
18:155-160.
2015
-
Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse..
18:173-181.
2015
-
Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue..
18:87-95.
2015
-
Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer..
18:161-166.
2015
-
Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension..
18:81-85.
2015
-
Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database..
17:91-96.
2014
-
Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression..
16:398.
2013
-
Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression..
16:285-291.
2013
-
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database..
16:391-397.
2013
-
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer..
16:357-361.
2013
-
African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center..
16:91-94.
2013
-
African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center..
16:91-94.
2013
-
Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy..
16:62-66.
2013
-
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center..
16:85-90.
2013
-
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center..
16:85-90.
2013
-
Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?.
15:380-385.
2012
-
Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry..
15:256-259.
2012
-
Predictive value of digital rectal examination for prostate cancer detection is modified by obesity..
14:346-353.
2011
-
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer..
14:206-218.
2011
-
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer..
14:192-205.
2011
-
Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men..
14:262-265.
2011
-
Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model..
14:97-104.
2011
-
Effect of intermittent fasting on prostate cancer tumor growth in a mouse model..
13:350-355.
2010
-
Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans..
13:362-368.
2010
-
Predicting non-organ-confined prostate cancer in men diagnosed after 2000..
13:248-251.
2010
-
Integrin involvement in freeze resistance of androgen-insensitive prostate cancer..
13:151-161.
2010
-
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer..
13:108-116.
2010
-
The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases..
13:87-93.
2010
-
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database..
12:259-263.
2009
-
Prostate Cancer and Prostatic Diseases. Report from Durham..
12:1.
2009
-
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer..
12:88-93.
2009
-
Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates..
11:13-19.
2008
-
Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy..
11:371-376.
2008
-
Targeted screening for prostate cancer in African-American men..
3:248-255.
2000
-
The role of pretreatment serum albumin to predict pathological stage and recurrence among radical prostatectomy cases..
3:186-190.
2000
-
Lateral biopsies added to the traditional sextant prostate biopsy pattern increases the detection rate of prostate cancer..
3:43-46.
2000
-
Update of clinical and basic science research on prostate cancer from the department of defense center for prostate disease research (DOD-CPDR)..
2:S22.
1999
-
Pathologic progression of autochthonous prostate cancer in the TRAMP model..
2:70-75.
1999
-
Pathology and bio markers of prostate cancer..
2:7-14.
1999
-
Use of multivariate models to improve prediction of pathologic stage for men with clinically localized prostate cancer..
1:301-306.
1998
-
Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy..
1:242-249.
1998
-
Standard vs conformal radiation therapy for adenocarcinoma of the prostate: no difference..
1:216-222.
1998
-
Prostate cancer in African American men..
1:109-118.
1998
-
Report from Durham..
13:1.
2010
-
Report from Durham..
12:209-210.
2009
-
WITHDRAWN: Can the conventional sextant prostate biopsy reliably diagnose unilateral prostate cancer in low-risk, localized, prostate cancer?
2008
-
Report from Durham..
11:211.
2008
-
Report from Durham..
11:1.
2008
-
cDNA microarray gene chip for prostate cancer and translational study in a prospective tissue bank and clinical longitudinal database..
3:S30.
2000
-
Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.
2022
-
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
2016